Skip to main content

Table 1 Demographic characteristics of the per-protocol cohort

From: Superior antigen-specific CD4+T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older

Characteristic TIV/AS03(≥65) TIV(≥65) TIV(18–40) Total
  (N = 62) (N = 66) (N = 44) (N = 172)
Age, months; mean (SD) 71.4 (5.5) 71.3 (5.3) 26.3 (5.1) 59.8 (20.4)
Gender; n (%) Female 31 (50) 27 (41) 24 (55) 82 (48)
Male 31 (50) 39 (59) 20 (46) 90 (52)
Race; n (%) American Indian or Alaskan native 0 (0) 0 (0) 0 (0) 0 (0)
African heritage/African American 0 (0) 0 (0) 0 (0) 0 (0)
Asian–Central/S. Asian heritage 0 (0) 0 (0) 2 (4.5) 2 (1.2)
Asian–E. Asian heritage 0 (0) 0 (0) 2 (4.5) 2 (1.2)
Asian–Japanese heritage 0 (0) 0 (0) 0 (0) 0 (0)
Asian–S. E. Asian heritage 0 (0) 1 (1.5) 1 (2.3) 2 (1.2)
Native Hawaiian/pacific islander 0 (0) 0 (0) 0 (0) 0 (0)
White - Arabic/N. African heritage 0 (0) 0 (0) 1 (2.3) 1 (0.6)
White - Caucasian/European heritage 62 (100) 64 (97) 37 (84) 163 (95)
  Other 0 (0) 1 (1.5) 1 (2.3) 2 (1.2)
  1. SD, standard deviation; TIV, trivalent influenza vaccine; TIV/AS03, AS03-adjuvanted trivalent influenza vaccine.